Market Overview

PROMETRIKA Extends Congratulations to Progenics Pharmaceuticals


First treatment approved for ultra-rare tumors

PROMETRIKA, LLC extends its congratulations to our colleagues at
Progenics Pharmaceuticals, Inc., on the recent approval of Azedra®
(iobenguane I 131). PROMETRIKA is honored and proud to have supported
Progenics through the integrated safety and efficacy analyses and
preparation of the NDA submission documents for the approval of Azedra.
The new treatment is approved for the treatment of adult and pediatric
patients 12 years and older with iobenguane scan-positive, unresectable,
locally advanced or metastatic pheochromocytoma or paraganglioma who
require systemic anticancer therapy. Azedra is the first treatment
approved in the US for these ultra-rare tumors. The FDA's announcement
of this milestone approval can be found at:

in 2003 and based in Cambridge, Massachusetts, PROMETRIKA is a unique
Clinical Research Organization, utilizing a collaborative approach to
clinical development and execution with a close-knit, highly-experienced
senior leadership team that remains involved throughout the duration of
each trial. PROMETRIKA's services include complete clinical operations
and clinical trial management, data management, pharmacovigilance,
biostatistics and programming, medical writing, and regulatory

About Progenics Pharmaceuticals -

Progenics develops innovative medicines and other technologies to target
and treat cancer, including: (1) therapeutic agents designed to treat
cancer (AZEDRA®, 1095, and PSMA TTC); (2) prostate-specific membrane
antigen ("PSMA") targeted imaging agents for prostate cancer (1404 and
PyLTM); and (3) imaging analysis technology. Progenics has two
commercial products, RELISTOR® (methylnaltrexone bromide) subcutaneous
injection for the treatment of opioid-induced constipation, which is
partnered with Salix Pharmaceuticals, Inc. (a wholly-owned subsidiary of
Bausch Health Companies Inc. (formerly known as Valeant Pharmaceuticals
International, Inc.)); and AZEDRA, for the treatment of patients with
unresectable, locally advanced or metastatic pheochromocytoma or
paraganglioma (rare neuroendocrine tumors of neural crest origin) who
require systemic anticancer therapy.

View Comments and Join the Discussion!